Koers Provectus Biopharmaceuticals Inc Nyse
Aandelen
US74373P1084
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2022 | 0,99 0,93 | Omzet 2023 | 0,56 0,52 | Marktkapitalisatie | 40,27 mln. 37,67 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -3 mln. -2,81 mln. | Nettowinst (verlies) 2023 | -3 mln. -2,81 mln. | EV/omzet 2022 | 48.121.944 x |
Nettoschuld 2022 | 2,16 mln. 2,02 mln. | Nettoschuld 2023 | 2,95 mln. 2,76 mln. | EV/omzet 2023 | 77.502.175 x |
K/w-verhouding 2022 |
-12,8
x | K/w-verhouding 2023 |
-13
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 90,58% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 71 | 27-04-18 |
Eric A. Wachter
FOU | Founder | 61 | 01-01-02 |
Heather Raines
DFI | Director of Finance/CFO | 58 | 01-08-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eric A. Wachter
FOU | Founder | 61 | 01-01-02 |
John W. Lacey
BRD | Director/Board Member | 76 | 27-04-18 |
President | 55 | 03-04-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |
- Beurs
- Aandelen
- Koers PVCT
- Koers